AlzTest: Overcoming Barriers to Implementation of Blood-Based Biomarkers for Alzheimer’s Disease
Validating blood-based Alzheimer’s diagnostics across ethnicities and care settings in the Netherlands
AlzTest is a new public-private partnership that brings together Amsterdam UMC, Roche Diagnostics, and Fujirebio Europe to prepare for the clinical implementation of innovative blood-based tests for Alzheimer’s disease. The project aims to validate these novel diagnostics across diverse ethnic groups and different healthcare settings, ensuring that future blood tests for Alzheimer’s are accurate and accessible for all patients in the Netherlands.
Dementia is a major health challenge, affecting over 310,000 people in the Netherlands, with numbers expected to double by 2030. Alzheimer’s disease is the most common cause, responsible for 70% of cases. Early and accurate diagnosis is crucial for timely access to care, prevention, and new treatments. Recent advances have led to blood tests with over 90% accuracy for detecting Alzheimer’s pathology, but their performance in real-world, diverse populations and various care settings remains unknown. Ensuring these tests work equally well for all ethnicities and in all healthcare environments is essential for fair and effective care.
The project will analyse blood-based biomarkers in large, ethnically diverse cohorts and compare their performance in primary, secondary, and tertiary care. By using data from the HELIUS study and clinical cohorts, AlzTest will determine whether ethnicity or care setting influences test accuracy, and whether reference values need adjustment. The approach includes head-to-head comparisons of different diagnostic platforms and collaboration with public health experts to ensure broad relevance.
The main deliverables are validated blood-based biomarker tests for Alzheimer’s disease, updated reference values for diverse populations, and clear recommendations for their use in different healthcare settings. These results will pave the way for the responsible and equitable implementation of blood tests for Alzheimer’s disease in Dutch clinical practice.
Other projects
In each PPP project, research institutions, businesses and healthcare organisations work together on a specific health challenge. Browse the full project overview.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We have received your message
We will contact you within 3 to 4 working days. If your question is urgent, please contact us directly. Below is the contact option that best matches your subject.
Start again
Something went wrong while sending the form. Please try again.